Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.40 |
| ▸ | PRKCG | P05129 | 3/20 | 0.40 |
| ▸ | PRKCB | P05771 | 3/20 | 0.40 |
| ▸ | PRKCA | P17252 | 3/20 | 0.40 |
| ▸ | PRKCH | P24723 | 3/20 | 0.40 |
| ▸ | PRKCI | P41743 | 3/20 | 0.40 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1773202 | 0.88 | SLC22A12 (0.44) | KCNA3KDM4EMAPKAPK2CYP3A4CYP2D6 | |
| SCHEMBL1056365 | 0.81 | ALDH1A1 (0.46) | KCNA3KDM4EPTGS1MEN1KMT2A | |
| SCHEMBL29937164 | 0.81 | ALDH1A1 (0.46) | KCNA3KDM4EPTGS1MEN1KMT2A | |
| SCHEMBL28598940 | 0.80 | PTGS1 (0.48) | KCNA3KDM4EMAPKAPK2CYP3A4CYP2D6 | |
| SCHEMBL9089451 | 0.80 | KCNA3 (0.48) | KCNA3KDM4EMAPKAPK2CYP3A4CYP2D6 | |
| SCHEMBL18318687 | 0.80 | PTGS1 (0.38) | KDM4EMAPKAPK2CYP3A4CYP2D6SUCNR1 | |
| SCHEMBL1773200 | 0.80 | TNF (0.44) | KCNA3KDM4EMAPKAPK2CYP3A4CYP2D6 | |
| Hydrogen Sulfide SCHEMBL27507715 | 0.80 | ALDH1A1 (0.45) | KCNA3KDM4EPTGS1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL9087780 | 0.79 | KCNA3 (0.47) | KCNA3KDM4EMAPKAPK2CYP3A4CYP2D6 | |
| SCHEMBL28393087 | 0.78 | KCNA3 (0.49) | KCNA3KDM4EMAPKAPK2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102617-B2 | Antimicrobial agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2015-08-11 | — | — | US | disclosed |
| US-9102617-B2 | Antimicrobial agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2015-08-11 | — | — | US | disclosed |
| US-20130109713-A1 | ANTIMICROBIAL AGENTS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY | 2013-05-02 | — | — | US | disclosed |
| US-20130109713-A1 | ANTIMICROBIAL AGENTS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY | 2013-05-02 | — | — | US | disclosed |
| WO-2011163610-A2 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-12-29 | — | — | WO | disclosed |
| US-8026241-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20100081650-A1 | Antimicrobial Compounds | AXTEN JEFFREY MICHAEL | 2010-04-01 | — | — | US | disclosed |
| US-7622481-B2 | Antibacterial compounds | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| US-7582761-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090143575-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | BALAN CHENERA | 2009-06-04 | — | — | US | disclosed |
| US-5968985-A | INHIBITORS OF SODIUM ION/HYDROGEN ION EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-19 | — | — | US | disclosed |
| US-RE36256-E | ADMINISTERING ARYL-SUBSTITUTED QUINOXALINE DERIVATIVES AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5795889-A | INHIBITING CELL GROWTH WITH ENZYME INHIBITORS FOR SKIN DISORDERS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-5656643-A | QUINOLIN PYRIDINE DERIVATIVES; USEFUL FOR TREATING CANCER, LEKEMIA, PSORIASIS, INFLAMMATORY DISODERS, BONE DISORDERS, ATHEROSCLEROSIS AND RESTENOSIS; CONTROLLS CELLULAR REPRODUCTION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-08-12 | — | — | US | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0773927-A2 | BENZOYLGUANIDINE DERIVATIVES AS MEDICAMENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996004241-A2 | BENZOYLGUANIDINE DERIVATIVES AS MEDICAMENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-02-15 | — | — | WO | disclosed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | disclosed |
| US-5409930-A | Inhibits abnoramal cell proliferation; dimethoxyquinoline/ dimethylquinoline/ quinolineoxide/ and quinoxaline derivatives | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-04-25 | — | — | US | disclosed |
| WO-1992020642-A1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109713-A1 | ANTIMICROBIAL AGENTS | RPS4X, RPS4Y1, MRPL21 | KCNA3 2164/4885KDM4E 2209/4885MAPKAPK2 4288/4885 |
| US-20090143575-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPV3, TRPV2 | KCNA3 55/4885KDM4E 3444/4885MAPKAPK2 1752/4885 |
| US-20100081650-A1 | Antimicrobial Compounds | ELANE, NISCH, PIGS | KCNA3 4464/4885KDM4E 4273/4885MAPKAPK2 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.